Evidence map›Paper›PMID 41080362›Full record

ArticleCureus2025

Persistent Respiratory Symptoms Post-COVID-19 in a Non-Hodgkin Lymphoma Patient: A Case Report.

Ilias E Dimeas, Styliani Papra, George Dimeas, Ioannis Pantazopoulos, Zoe Daniil

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ilias E DimeasDepartment of Pulmonology, University Hospital of Larissa, Larissa, GRC.
Styliani PapraDepartment of Internal Medicine, AHEPA University General Hospital, Thessaloniki, GRC.
George DimeasDepartment of Internal Medicine, General Hospital of Karditsa, Karditsa, GRC.
Ioannis PantazopoulosDepartment of Emergency Medicine, University of Thessaly, University General Hospital of Larissa, Larissa, GRC.
Zoe DaniilDepartment of Pulmonology, University Hospital of Larissa, Larissa, GRC.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Persistent fever and pulmonary infiltrates in immunocompromised patients pose a major diagnostic challenge, especially in those receiving anti-CD20 therapy that impairs humoral immunity. We present a 66-year-old man with non-Hodgkin lymphoma on obinutuzumab and lenalidomide who developed prolonged fever, dry cough, and bilateral ground-glass opacities after COVID-19 infection. The differential diagnosis included persistent viral pneumonitis, post-COVID organizing pneumonia, drug-induced lung injury, opportunistic infection, and lymphoma progression. Initial corticosteroid therapy for suspected organizing pneumonia led to partial improvement, but symptoms relapsed during tapering. Bronchoscopy and laboratory analysis confirmed invasive pulmonary aspergillosis and profound hypogammaglobulinemia, while persistent SARS-CoV-2 PCR positivity suggested impaired viral clearance due to B-cell depletion. Treatment with isavuconazole, broad-spectrum antibiotics, corticosteroids, and intravenous immunoglobulin resulted in clinical, radiological, and immunological recovery. This case highlights the importance of maintaining a broad differential diagnosis in immunocompromised patients with unresolved post-COVID pulmonary symptoms and demonstrates that prompt recognition of hypogammaglobulinemia and timely immunoglobulin replacement can be pivotal for recovery.

Indexed as

anti-cd20covid 19dyspneafeverimmunocompromised patientnon hodgkin's lymphomaobinutuzumabpost-covid symptoms

Identifiers

PMID41080362
PMCPMC12510798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.